Close Menu

NEW YORK (GenomeWeb) – Diagnostics manufacturer Quidel reported after the close of the market on Wednesday that its fourth quarter revenues rose 15 percent year over year, due primarily to a steep rise in cardiac immunoassay revenues as well as increased sales of rapid immunoassay and molecular diagnostic products.

For the three months ended Dec. 31, 2018 Quidel reported revenues of $132.6 million, up from $114.9 million in Q4 2017, and beating the consensus analyst estimate of $132.1 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.